6,239 reports of this reaction
2.2% of all SPIRONOLACTONE reports
#6 most reported adverse reaction
DIZZINESS is the #6 most commonly reported adverse reaction for SPIRONOLACTONE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 6,239 FDA adverse event reports linking SPIRONOLACTONE to DIZZINESS. This represents approximately 2.2% of all 279,694 adverse event reports for this drug.
SPIRONOLACTONE has an overall safety score of 85 out of 100. Patients taking SPIRONOLACTONE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for SPIRONOLACTONE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for SPIRONOLACTONE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 6,239 FDA reports for SPIRONOLACTONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.2% of all adverse event reports for SPIRONOLACTONE, making it a notable side effect.
If you experience dizziness while taking SPIRONOLACTONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.